PB Pharma GmbH
Pharmaceutical Companies · Rhein-Kreis Neuss
PB Pharma GmbH is a pharmaceutical company based in Rhein-Kreis Neuss, North Rhine-Westphalia, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
PB Pharma GmbH Address & Contact
PB Pharma GmbH at a Glance
PB Pharma GmbH is a German pharmaceutical company based in the Rhein-Kreis Neuss, North Rhine-Westphalia. Founded in 2001, the company has made a name for itself as a competent partner in the pharmaceutical industry. Due to its strategic location in the heart of the Rhineland, PB Pharma is optimally positioned to serve both national and international markets. The close collaboration with a variety of industry players enables PB Pharma to quickly respond to market changes and offer innovative solutions.
Field of Activity & Products
PB Pharma specializes in pharmaceutical trade and consulting. The product range includes prescription medications, over-the-counter drugs, and high-quality health products. In addition, the company offers tailored solutions in the area of pharmaceutical supply, ranging from development to approval and marketing.
Notably, the close collaboration with pharmaceutical companies, pharmacies, and hospitals is emphasized. PB Pharma not only acts as a supplier of medicines but also as a strategic partner providing advice on drug safety and compliance. This includes training for professionals and the development of informational materials to ensure the safe use of medications.
- Pharmaceutical Trade: Sale of prescription and over-the-counter medications.
- Consulting: Support in the approval and marketing of pharmaceutical products.
- Logistics: Efficient distribution channels for timely delivery to pharmacies and hospitals.
- Pharmaceutical Quality Assurance: Ensuring compliance with quality standards according to Good Manufacturing Practice (GMP).
History & Regulation
PB Pharma GmbH was founded in 2001 by a group of experienced pharmacists and business economists and has continuously developed since then. In recent years, the company has formed several strategic partnerships with renowned pharmaceutical manufacturers and expanded its product portfolio. The company is under strict supervision by the responsible North Rhine-Westphalian authorities and the Federal Institute for Drugs and Medical Devices (BfArM).
To ensure the high quality of its products and services, PB Pharma holds all necessary licenses and approvals in accordance with the requirements of the Medicines Act (AMG) and the Good Distribution Practice (GDP) guidelines. Regular inspections and certifications by external bodies guarantee that all products comply with European regulations. Furthermore, PB Pharma is actively working on the implementation of innovations in the field of digital health to meet the demands of a dynamic market.
Regional Importance
PB Pharma GmbH plays a significant role in the regional healthcare provision of the Rhein-Kreis Neuss. The region is known for its dense cluster of health and pharmaceutical companies, providing a fertile ground for collaborations and innovations in the healthcare sector. Through close cooperation with local institutions, PB Pharma can specifically address the needs of the region and offer tailored solutions.
Moreover, PB Pharma actively promotes the training of young talent in the pharmaceutical field by offering internship positions and training opportunities. This contributes to securing a high level of expertise in the region and strengthens the pharmaceutical landscape of the Rhineland.
Further information: Pharmaceutical companies in North Rhine-Westphalia or all pharmaceutical companies in Germany on Sanoliste.
Frequently asked questions about PB Pharma GmbH
What does PB Pharma GmbH do?
PB Pharma GmbH hat sich on Vermarktung and distribution of Betäubungswithteln spezialisiert. Schwerpunkt liegt on Atemwegstherapeutika and Schmerzwithteln. Sie kontrolliert the Bedingungen atm Import, sorgt for the Konfektionierung and Umbeschriftung of Beipackzetteln and aboutnimmt Lagerung and Auslieferung.
PB Pharma GmbH on social media
More Pharmaceutical Companies in Rhein-Kreis Neuss
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.